Global Stem Cells Group in Final Stages of Development of Closed System to Isolate Stem Cells

Share Article

Global Stem Cells Group has announced that it is in the final stages of design and development of a new closed system for the isolation of adipose derived stem cells.

stemlab,stem cells, stem cell therapies,liposculpture,plastic surgery

Global Stem Cells Group

After years of development, Global Stem Cells Group’s simple and quick system for obtaining SVF is expected to change the standard for harvesting and purification of adipose tissue.

Global Stem Cells Group announced that its scientific team is in the final design and development stages of a new closed system for isolating adipose-derived stem cells. The announcement starts a new phase toward launching the simple, quick system for obtaining stromal vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess adipose tissue.

Lipoaspirate, contains a large population of adipose derived stem cells (ADSCs), which share a number of similarities with bone marrow stromal cells, including the capacity for multilineage differentiation.

After years of development, Global Stem Cells Group’s simple and quick system for obtaining SVF is expected to change the standard for harvesting and purification of adipose tissue, according to GSCG CEO Benito Novas.

Adipose tissue is a rich and convenient source of stem cells for use in regenerative medicine therapeutic treatments. Thanks to their wide availability and ability to differentiate into other tissue types—including bone, cartilage and muscle, ADSCs have the potential to be used in a wide variety of applications. Adipose stem cells have been used in treatments for a wide range of medical conditions, including osteoarthritis, diabetes mellitus, heart disease, and for soft tissue regeneration and reconstruction after mastectomies and injuries.

The Global Stem Cells system is specifically developed to isolate ADSCs or SVF in a closed, sterile device designed for safe, effective and economic automated adipose tissue processing. Harvesting ADSCs from lipospirate without expensive machines and potentially harmful enzymes can open a range of applications in regenerative surgery, thanks to the small amount of tissue needed for a procedure.

The new system is also designed to meet the criteria that ASCs require to be considered a viable option in regenerative medicine, including:

1.    Abundance (millions to billions of cells are needed).
2.    Ease of harvest, through minimally invasive procedures
3.    Ability to differentiate into multiple cell types which can be regulated and reproduced in vitro.
4.    Safe to transplant to a different site of the autologous host or even an allogenic host.
5.    No conflict with current Good Manufacturing Principles (GMP) (during procurement, culture or transplantation.

The high concentrations of stem cells available in adipose tissue ensure an abundance of ASCs ranging in the millions per unit volume. There is the added advantage of eliminating the need to culture cells in a laboratory over days in order to get the desired number of ASCs to achieve what is called “therapeutic threshold” for therapeutic benefit.

For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Benito Novas

Liz Ernst
Email >
since: 09/2009
Follow >
Like >

Follow us on
Visit website